Good Care

For Psoriatic Arthritis

Recent progress in understanding the course of psoriatic arthritis (PsA) has lead to breakthroughs in therapies. Yet the needs of many people living with PsA are still unmet. Through this project, IFPA aims to join forces with rheumatologists and the patient community to raise awareness of new treatment guidelines, and ultimately improve quality of life for people with PsA around the world.

Do you feel confident discussing treatment guidelines with your healthcare provider?

The new GRAPPA guidelines (2022) assign equal importance to each clinical symptom (also called domains) and comorbidities.

What do the current GRAPPA recommendations advocate for?

Why is this important?

  • The current treatment guidelines take into consideration previous therapies, and associated comorbities that impact the quality of life to support therapy decision-making.
  • IFPA is looking to co-create educational materials based on the latest evidence that is useful to people living with PsA theire care-givers and Health Care providers.
  • The project team welcomes you to participate in a webinar to mark the materials launch.
20220930223115 IMG 1730 2

This project is supported by

UCB Pharma has provided financial support through an unrestricted grant for the delivery of the First phase of the Psoriatic Arthritis Awareness project, also known as the "Good Care for the Psoriatic Arthritis" Project. UCB Pharma had no influence or input over the content, including the selection of project members and the development of all associated assets, such as videos, podcasts, and articles. The support from UCB Pharma was solely in the form of an unrestricted grant.